Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Avadomide in Renal Impairment
NCT03097016Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avadomide in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM) and 1 more, sponsored by Celgene Corporation. Primary endpoints: Time to Maximum Plasma Concentration up to 72 hours, Maximum Plasma Concentration up to 72 hours and 7 more. Started Mar 2017; status: completed.
02
Drugs
avadomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT03097016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097016.